Forum: Arrowhead Research » Forum Arrowhead Research geopend

DeZwarteRidder 10 februari 2025 14:50

DeZwarteRidder

Lid sinds: 29 jun 2012

Laatste bezoek: 10 feb 2025
Aanbevelingen

Ontvangen: 24091

Gegeven: 10531
Aantal posts: 101.988

quote:
Gerard1968 schreef op 10 februari 2025 14:47:
ir.arrowheadpharma.com/news-releases/...

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
February 10, 2025
PDF Version

PASADENA, Calif.--(BUSINESS WIRE)--Feb. 10, 2025-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.

Summary Financial Terms

Upon closing, Arrowhead receives a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share. Arrowhead will also receive $250 million to be paid in annual installments of $50 million over 5 years. Arrowhead also has the potential to receive $300 million in near-term payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study of ARO-DM1, which Arrowhead is on track to achieve during the next 12 months.

Arrowhead is eligible to receive development milestone payments of between $110 million and $410 million per program and sales milestone payments of between $500 million and $700 million per program. Arrowhead is also eligible to receive tiered royalties on commercial sales up to the low double digits.

zoek uitleg